Sign in to view content

Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS

Video
Published 2024

Related

Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2021
Is It Necessary to Peel Internal Limiting Membrane in Diabetic Vitrectomy
Stanley Chang, MD
Updates from the Field
2022
Cost of Initial Aflibercept, Laser, or Observation in Eyes With Diabetic Macular Edema and Good Vision Based on Management Approaches in Protocol V
Jennifer K. Sun, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more